Description
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. Appearance:SolidIC50& Target:Neuropilin-1In Vitro:ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1 by 82% at 100 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In Vivo:ATWLPPR (400 µg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes. ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) iBiological Activity:ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes